Between the voriconazole and placebo groups , there were no significant differences in the number of severe exacerbations ( @ vs @ per patient per year , respectively ; mean difference , @ ; @ % CI , @-@ @ ) , quality of life ( change in Asthma Quality of Life Questionnaire score , @ vs @ ; mean difference between groups , @ ; @ % CI , -@ to -@ ) , or any of our secondary outcome measures .